Roth David 4
4 · Syros Pharmaceuticals, Inc. · Filed Nov 4, 2024
Insider Transaction Report
Form 4
Roth David
Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-10-31−18,875→ 0 total→ Common Stock (18,875 underlying) - Exercise/Conversion
Common Stock
2024-10-31+18,875→ 18,875 total - Tax Payment
Common Stock
2024-10-31$2.09/sh−6,776$14,162→ 12,099 total
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.